Gilead Sciences, a privately owned company headquartered in the US, was founded in 1987. With approximately 13,690 employees, the company functions as a tier 1 media tech buyer. Gilead Sciences specializes in biotechnology research, focusing on bringing forward medicines for life-threatening diseases. The company's operations involve its employees collaborating through science to address medical challenges.
On March 15, 2026, South Africa began efforts to locally produce lenacapavir, Gilead Sciences' long-acting HIV prevention drug, aiming to strengthen regional manufacturing and broaden access. Previously, on March 14, Zacks Research analysts increased their Q1 2027 earnings per share estimates for Gilead Sciences to $2.07 from their prior estimate of $2.06. This follows news from March 13 concerning Gilead's cell therapy franchise, which includes Yescarta and Tecartus. Sales from this unit decreased 7% year-over-year to $1.8 billion in 2025, with Yescarta sales falling 5% to $1.5 billion due to competitive headwinds. Earlier, on March 12, Gilead Sciences partnered with the Trump administration and the Global Fund to deliver lenacapavir to two million at-risk individuals in ten African countries over three years.
Similar Companies
Subscribe for full access to Gilead Sciences's profile
Gilead Sciences offers 2 products in the media and telecoms services industry. Gilead Sciences's product portfolio comprises of media and TV services.
Subscribe for full access to Gilead Sciences's products in full detail
Subscribe for full access to Gilead Sciences's revenue in full detail
Subscribe for full access to Gilead Sciences's products in full detail 
